A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Minitransplants and cell-based therapies for malignant and nonmalignant disorders
Shimon Slavin,Arnon Nagler,Elisabeth Naparstek,Memet Aker,Gabriel Cividalli,Gabor Varadi,Aliza Ackerstein,Simcha Samuel,Avraham Amar,Chaim Brautbar,Reuven Or +10 more
Journal ArticleDOI
Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT.
Xavier Poiré,Myriam Labopin,Emmanuelle Polge,Edouard Forcade,Arnold Ganser,Liisa Volin,Mauricette Michallet,Didier Blaise,Ibrahim Yakoub-Agha,Johan Maertens,Carlos Richard Espiga,Jan J. Cornelissen,Jürgen Finke,Mohamad Mohty,Jordi Esteve,Arnon Nagler +15 more
TL;DR: In multivariate analysis, factors associated with worse overall survival and leukemia-free survival across the four groups were active disease, age, monosomal karyotype, and abn(17p).
Journal ArticleDOI
Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia.
Alois Gratwohl,Rafael F. Duarte,John A. Snowden,Anja van Biezen,Helen Baldomero,Jane F. Apperley,Jan J. Cornelissen,Hildegard Greinix,Eoin Mc Grath,Mohamad Mohty,Nicolaus Kroeger,Arnon Nagler,Dietger Niederwieser,Hein Putter,Ronald Brand +14 more
TL;DR: Overall survival was significantly associated with selection steps and completeness of information, and pre-transplantation risk factors determine survival, independent of transplant techniques, in patients with an allogeneic HSCT.
Journal ArticleDOI
Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Anas Younes,Joshua Brody,Cecilia Carpio,Armando López-Guillermo,Dina Ben-Yehuda,A. Burhan Ferhanoglu,Arnon Nagler,Muhit Ozcan,Irit Avivi,Francesc Bosch Albareda,María Dolores Caballero Barrigón,Aisha Masood,Michael Streit,John Alvarez,Rob Ceulemans,Behzad Kharabi Masouleh,Sriram Balasubramanian,Michael Schaffer,Shean-Sheng Wang,Nele Fourneau,Wojciech Jurczak +20 more
TL;DR: The combination of oral ibrutinib (420 mg or 560 mg qd) and IV nivolumab (every 14 days) displayed an acceptable safety profile and was found to be effective in patients with relapsed or refractory R/R high-risk chronic lymphocytic leukemia.
Journal ArticleDOI
Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies
Pier Luigi Zinzani,Armando Santoro,Luigina Mollica,Sirpa Leppä,George A Follows,Georg Lenz,Won Seog Kim,Arnon Nagler,Panayiotis Panayiotidis,Judit Demeter,Franck Morschhauser,Javier Munoz,Ashok Miriyala,A. Benson,J. Garcia-Vargas,Barrett H. Childs,Martin Dreyling +16 more
TL;DR: The Phase II CHRONOS-1 study in pts with indolent lymphoma treated with copanlisib demonstrated an objective response rate of 59.2% with manageable safety and low rates of severe adverse events (AEs) and no increased incidence of g≥3 events with prolonged exposure.